The AI medical field is surging: giants compete and the wave of innovation sweeps across.

Recently, the field of AI medical care has become the focus of science and technology and industry, and many companies have laid out their plans and kept moving. From Baichuan Intelligent's release of a new generation of medical model, to OpenAI's acquisition of Torch, a health care startup, to Anthropic's entry into the medical field, as well as the deep cooperation between NVIDIA and Lilly in AI pharmacy, and the active expansion of Alfred Ant in the field of health management, AI medical care is welcoming unprecedented development opportunities.

Baichuan Intelligence: M3 Model Leads New Medical Reform

On January 13th, Wang Xiaochuan, founder and CEO of Baichuan Intelligent, released a new generation of open source medical enhanced language model, Baichuan-M3, at the media communication meeting for the release of the model. This model ranks first in consultation ability, medical illusion, Healthbench and Healthbench Hard evaluation, surpassing GPT-5.2 of OpenAI and even surpassing human doctors in all aspects.

Wang Xiaochuan said that since it started its business in 2023, despite many doubts, Baichuan Intelligent firmly believes in the potential of AI in the medical field. With the recent entry of companies such as OpenAI and Anthropic into the medical field, AI medical care has entered the application field and become the main line of AI application. M3 model has the original "end-to-end" serious inquiry ability for the first time, which can actively ask questions and approach layer by layer like a doctor, obtain key medical history and risk signals, and then conduct in-depth medical reasoning. The evaluation shows that its consultation ability is significantly higher than the average level of real doctors. In addition, M3 has surpassed GPT-5.2 in the field of low hallucination, with the lowest hallucination rate in the world.

At present, Baixiaoying, a subsidiary of Baichuan Intelligent, has been connected to M3 synchronously, opening related capabilities to doctors and patients. Wang Xiaochuan revealed that Baichuan Intelligent's exploration in the field of AI medical care is more inclined to the "serious medical care" scene, and put forward the "serious inquiry paradigm" and "SCAN principle", which systematically makes the thinking process highly dependent on experience in clinical inquiry through Safety Stratification, Clarity Matters, Association & Inquiry and standardized output.

Wang Xiaochuan also pointed out that there are four major pain points in the current domestic medical industry: insufficient good doctors, unequal doctor-patient relationship, insufficient diagnosis and treatment capacity at the grass-roots level and limited medical development. He believes that the outbreak of AI has made it possible to solve these problems. In the future, the increment and clients of AI medical care will be more outside the hospital, and directly serving patients will be the most efficient way.

OpenAI: Acquisition of Torch, Plus AI Medical

OpenAI's actions in the field of AI medical care are equally eye-catching. On Monday, OpenAI announced on the social media X platform that it had acquired Torch, a medical technology startup. The acquisition represents a strategic move by OpenAI to strengthen its capabilities in the healthcare sector, aiming to expand its AI technology application to various industries.

Although OpenAI did not disclose the specific acquisition amount, according to industry sources, the acquisition amount of this transaction is about 60 million US dollars, and there are also rumors that the acquisition amount is about 100 million US dollars. Torch is committed to building a "unified medical memory" system for the AI industry, integrating patient health data scattered in different suppliers and formats, and helping users to view and analyze health data from different channels.

Torch's products currently rely in part on OpenAI's artificial intelligence model to generate personalized medical advice based on user data. Torch employees will join OpenAI after the acquisition. Ilya Abyzov, CEO of Torch, said that technology and ideas will serve hundreds of millions of users who use ChatGPT to consult health problems every week.

It is worth mentioning that before announcing the acquisition of Torch, OpenAI just launched a new function "ChatGPT Health", which is integrated in ChatGPT. It is an independent space dedicated to health-related conversations and can connect electronic medical records and various health applications. In addition, OpenAI has also released a number of enterprise-level products for medical institutions, marking its ambition to continuously increase its "AI+ medical" business.

Anthropic: Launched Claude medical service and entered the medical field.

After OpenAI, the AI startup Anthropic followed closely into the medical field. According to Bloomberg News, Anthropic announced on Sunday the launch of Claude medical service that meets HIPAA standards, which can be used by hospitals, medical institutions and consumers to process protected health data.

Anthropic's medical functions include integrating scientific databases, enhancing biological research capabilities, and allowing users to export health data from applications such as Apple Health and Function Health. The company promised not to use medical user data to train the model, and all medical responses quoted authoritative publications.

Mike Krieger, chief product officer of Anthropic, said that the medical field is one of the economic fields where AI can have the greatest impact, and the new tools are designed to let people gain more knowledge. ChatGPT Health of OpenAI also emphasizes auxiliary positioning to help users deal with daily health problems.

Anthropic has made initial progress in medical institutions. Banner Health, one of the largest non-profit medical systems in the United States, has more than 22,000 clinical medical service providers using Claude, and 85% of them report faster and more accurately.

NVIDIA and Lilly: Cooperation to Accelerate AI Pharmaceutical

At the 44th JPMorgan Chase Global Health Conference, NVIDIA and Lilly announced that they would invest 1 billion US dollars in the next five years to build a joint research laboratory in the San Francisco Bay Area, aiming at accelerating the application of artificial intelligence in the pharmaceutical industry.

As early as last October, Lilly announced that it would deploy the largest and most powerful AI pharmaceutical factory in the world and adopt DGX super cluster based on Blackwell architecture in NVIDIA. David Ricks, chairman of Lilly, said that the combination of massive data and scientific knowledge with NVIDIA's computing power and modeling expertise is expected to revolutionize the drug research and development model.

The cooperation between the two parties will focus on building a continuous learning system, which will closely connect Lilly's intelligent wet laboratory with the computing dry laboratory to realize all-weather artificial intelligence-assisted experiments. The core value of AI pharmaceutical lies in greatly improving the efficiency of drug early research. Taking Yingsi Intelligent Pharma.AI as an example, it can greatly shorten the time from target discovery to pre-clinical candidate drug confirmation, thus greatly improving the input-output ratio in the early research stage.

Ah Fu Ant: A New AI Star in Health Management

In China, A Fu Ant is also actively expanding in the field of health management. On January 12, a survey showed that over 70% of the doctors interviewed expressed their willingness to recommend the public to use AI doctors to solve daily basic health problems, and 62% of the doctors interviewed were already using AI doctors to assist their work.

At present, more than 500 doctors in 3A hospitals have set up their own "AI avatars" on the platform of Healthy AI Ant Afu, which can answer users' inquiries online 7*24 hours. Ant Group announced that its AI health application AQ brand has been upgraded to "Ant Ah Fu", and released a new version of the APP, upgrading the three functions of health question and answer, health companionship and health service.

The new version of "A Fu Ant" focuses on "Health+Strategy", shifting from AI tools to AI healthy friends to help users manage their own and their family's health. Users can record their health status through the "health diary" module, open access to nine smart devices, and synchronize daily health data. In addition, the new version of "Afu" has also launched two companion functions, namely "small health goals" and "small health reminders". Users can set health goals such as exercise, diet and living habits, and Afu will customize the exclusive plan like a "personal trainer" and remind them daily.

Present situation and trend of AI medical treatment

In Huang Renxun's view, artificial intelligence is changing all walks of life, and its most far-reaching field will be life science. In fact, the field of life sciences benefited by AI goes far beyond the pharmaceutical industry itself. In addition to drug discovery, the two sides will explore opportunities to apply artificial intelligence in clinical development, manufacturing and commercial operations in the future, including the use of physical artificial intelligence and robotics in factories.

The industry believes that the AI medical industry is welcoming a golden period of development. Innovative achievements such as medical imaging AI-assisted diagnosis, intelligent surgical robots, and drug research and development AI platforms have accelerated, and the upstream and downstream of the industrial chain have worked together to form a complete ecology from algorithm research and development, data services to product applications.

However, the development of AI medical care also faces some challenges. Zhang Wenhong explicitly opposed the systematic inclusion of AI in the daily diagnosis and treatment of hospitals at the Hong Kong Alpine College Forum, arguing that AI can only be an auxiliary tool. He is worried that young doctors will rely on AI to draw conclusions from the internship stage, skip the complete clinical thinking training, and have no ability to identify the right or wrong diagnosis of AI in the future.

Despite this, the development momentum of AI medical care is still strong. Industry sources pointed out that medical devices, innovative drugs and other fields still need to wait for centralized procurement policy optimization or heavy technological breakthroughs, but the fields combined with innovative technologies are still worthy of attention. Under the tide of AI technology, medicine is expected to release new growth logic, and brain-computer interface, early tumor screening and AI medical treatment are developing rapidly. There are also people in the industry who are optimistic about the revolutionary potential of AI+ medical care in pharmacy, basic research, diagnosis and health management.

Tag

The AI medical field is welcoming unprecedented development opportunities, and many companies have laid out their plans and kept moving. From the M3 model of Baichuan Intelligent to the acquisition of Torch by OpenAI, to the entry of Anthropic into the medical field, as well as the cooperation between NVIDIA and Lilly and the active expansion of Alfred Ant, AI medical care is becoming the focus of scientific and industrial circles. Despite some challenges, the development momentum of AI medical care is still strong, and it is expected to bring more innovations and breakthroughs to human health in the future.

Maxipcb is a professional PCB and PCBA manufacturing company. We provide RD and production products from PCB design to PCB manufacturing, PCB assembly to completion. If you have a good idea, please contact Maxipcb.